{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04261335",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CAMCR-014"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "jRCT2043190112",
            "SecondaryIdType": "Registry Identifier",
            "SecondaryIdDomain": "Japan Registry of Clinical Trials"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Nagoya University",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "The Clinical Trial of CL2020 Cells for Neonatal Hypoxic Ischemic Encephalopathy",
      "OfficialTitle": "The Evaluation of Safety and Tolerability of CL2020 in Neonatal Hypoxic Ischemic Encephalopathy Patients With Therapeutic Hypothermia in the Dose Escalation Clinical Trial",
      "Acronym": "SHIELD"
    },
    "StatusModule": {
      "StatusVerifiedDate": "September 2021",
      "OverallStatus": "Active, not recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 4, 2020",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2021",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "September 2023",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "February 1, 2020",
      "StudyFirstSubmitQCDate": "February 6, 2020",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "February 7, 2020",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "September 3, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "September 5, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Yoshiaki Sato",
        "ResponsiblePartyInvestigatorTitle": "MD, PhD, Associate Professor at Department of Center for Maternal Neonatal Care, Nagoya University Hospital",
        "ResponsiblePartyInvestigatorAffiliation": "Nagoya University"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Nagoya University",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Life Science Institute, Inc.",
            "CollaboratorClass": "UNKNOWN"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of this study is to evaluate the safety and the tolerability of CL2020 cells in hypoxic ischemic encephalopathy neonates with hypothermia therapy. In addition, we will evaluate the efficacy of CL2020 cells for infant development."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Hypoxia-Ischemia, Brain"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Hypoxia-Ischemia, Brain",
          "Infant, Newborn",
          "Mesenchymal Stem Cells"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignInterventionModelDescription": "3 + 3 dose escalation study design",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "9",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "CL2020 cells",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Intravenous injection of CL2020 cells",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: CL2020 cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "CL2020 cells",
            "InterventionDescription": "1.5 million or 15 million cells, IV on day 5 to 14 of birth",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "CL2020 cells"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Incidence of adverse events",
            "PrimaryOutcomeDescription": "Any adverse events are summarized.",
            "PrimaryOutcomeTimeFrame": "until 12 weeks after the administration"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Incidence of composite endpoints (death, continuous respiratory support, and continuous use of vasopressors or pulmonary vasodilators)",
            "SecondaryOutcomeDescription": "Incidence of composite endpoints is summarized.",
            "SecondaryOutcomeTimeFrame": "at 12, 26, 38, 52, and 78 weeks after administration"
          },
          {
            "SecondaryOutcomeMeasure": "Mortality",
            "SecondaryOutcomeDescription": "Mortality is summarized.",
            "SecondaryOutcomeTimeFrame": "all of the clinical trial period (up to 44 months)"
          },
          {
            "SecondaryOutcomeMeasure": "Overall survival",
            "SecondaryOutcomeDescription": "Overall survival is summarized.",
            "SecondaryOutcomeTimeFrame": "all of the clinical trial period (up to 44 months)"
          },
          {
            "SecondaryOutcomeMeasure": "Duration of continuous respiratory support",
            "SecondaryOutcomeDescription": "Duration of continuous respiratory support is summarized.",
            "SecondaryOutcomeTimeFrame": "up to 78 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Duration of continuous use of vasopressors or pulmonary vasodilators",
            "SecondaryOutcomeDescription": "Duration of continuous use of vasopressors or pulmonary vasodilators is summarized.",
            "SecondaryOutcomeTimeFrame": "up to 78 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "The composite score of cognitive scale, language scale, motor scale, social-emotional scale, and adaptive behavior scale in Bayley Scales of Infant and Toddler Development Third edition",
            "SecondaryOutcomeDescription": "Each composite scores are summarized. The higher scores mean a better outcome.",
            "SecondaryOutcomeTimeFrame": "78 weeks after administration"
          },
          {
            "SecondaryOutcomeMeasure": "The developmental quotient in Kyoto Scale of Psychological Development 2001",
            "SecondaryOutcomeDescription": "The developmental quotient is summarized. The higher scores mean a better outcome.",
            "SecondaryOutcomeTimeFrame": "78 weeks after administration"
          },
          {
            "SecondaryOutcomeMeasure": "Presence of 1) head control, 2) roll over, 3) sitting position, 4) crawl, 5) independent gait, and 6) meaningful words",
            "SecondaryOutcomeDescription": "Presence of each event is summarized.",
            "SecondaryOutcomeTimeFrame": "at 26, 38, 52, and 78weeks after administration"
          },
          {
            "SecondaryOutcomeMeasure": "Presence of spasticity",
            "SecondaryOutcomeDescription": "Presence of spasticity is summarized. Spasticity is the condition as below: increased muscle tone, or increased deep tendon reflex.",
            "SecondaryOutcomeTimeFrame": "at 12, 26, 38, 52, and 78 weeks after administration"
          },
          {
            "SecondaryOutcomeMeasure": "Presence of epilepsy",
            "SecondaryOutcomeDescription": "Presence of spasticity is summarized. The definition of epilepsy is the condition based on the International League Against Epilepsy.",
            "SecondaryOutcomeTimeFrame": "until 78 weeks after administration"
          },
          {
            "SecondaryOutcomeMeasure": "MRI score",
            "SecondaryOutcomeDescription": "MRI score is summarized. The scoring system is based on the report of Barkovich AJ, et al. (AJNR Am J Neuroradiol. 1998 ;19(1):143-9.) . The higher scores mean a worse outcome.",
            "SecondaryOutcomeTimeFrame": "at 2, and 78 weeks after administration"
          },
          {
            "SecondaryOutcomeMeasure": "Gross Motor Function Classification System (GMFCS) score",
            "SecondaryOutcomeDescription": "GMFCS score is summarized. The gross motor function can be categorized into 5 different level. The higher scores mean a worse outcome.",
            "SecondaryOutcomeTimeFrame": "at 78 weeks after administration"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAt least 36 weeks gestation, and either one of the following criteria (i.-iii.) i. Apgar score ≤5 at 10 minutes ii. Continued resuscitation for at least 10 minutes iii. pH <7.0 or base deficit ≥16 mmol/L in any blood sample obtained within 60 min of birth\nModerate or severe encephalopathy by a Sarnat criteria\nUndergone therapeutic hypothermia started before six hours of birth, and done for 72 hours continuously\nBirth weight ≥1,800 g\nHeart rate ≥100/min, and SpO2 ≥90 %\nAble to provide voluntary written consent after receiving adequate information about the study (consent will be obtained from an acceptable representative)\n\nExclusion Criteria:\n\nSuspected or confirmed severe congenital abnormalities or chromosomal anomaly\nPlanned to undergo surgery or radiation therapy\nScheduled to take systemic corticosteroids treatment for over five days\nBlood glucose ≥ 200 mg/dL\nParticipation in another clinical study (not exclude patients in observational studies)\nSuspected or confirmed active and severe infection\nPositive for HBs antigen, HCV antibody, HIV antibody, HTLV-1 antibody or syphilis serum reaction\nHistory of severe hypersensitivity or anaphylactic reaction\nSevere complications",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MaximumAge": "14 Days",
      "StdAgeList": {
        "StdAge": [
          "Child"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Yoshiaki Sato, MD, PhD",
            "OverallOfficialAffiliation": "Department of Center for Maternal Neonatal Care, Nagoya University Hospital",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Nagoya University Hospital",
            "LocationCity": "Nagoya",
            "LocationState": "Aich",
            "LocationZip": "466-8560",
            "LocationCountry": "Japan"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000001927",
            "ConditionMeshTerm": "Brain Diseases"
          },
          {
            "ConditionMeshId": "D000002545",
            "ConditionMeshTerm": "Brain Ischemia"
          },
          {
            "ConditionMeshId": "D000020925",
            "ConditionMeshTerm": "Hypoxia-Ischemia, Brain"
          },
          {
            "ConditionMeshId": "D000007511",
            "ConditionMeshTerm": "Ischemia"
          },
          {
            "ConditionMeshId": "D000000860",
            "ConditionMeshTerm": "Hypoxia"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000012818",
            "ConditionAncestorTerm": "Signs and Symptoms, Respiratory"
          },
          {
            "ConditionAncestorId": "D000002493",
            "ConditionAncestorTerm": "Central Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000002561",
            "ConditionAncestorTerm": "Cerebrovascular Disorders"
          },
          {
            "ConditionAncestorId": "D000014652",
            "ConditionAncestorTerm": "Vascular Diseases"
          },
          {
            "ConditionAncestorId": "D000002318",
            "ConditionAncestorTerm": "Cardiovascular Diseases"
          },
          {
            "ConditionAncestorId": "D000002534",
            "ConditionAncestorTerm": "Hypoxia, Brain"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M9695",
            "ConditionBrowseLeafName": "Ischemia",
            "ConditionBrowseLeafAsFound": "Ischemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3337",
            "ConditionBrowseLeafName": "Hypoxia",
            "ConditionBrowseLeafAsFound": "Hypoxia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M4946",
            "ConditionBrowseLeafName": "Brain Ischemia",
            "ConditionBrowseLeafAsFound": "Ischemia, Brain",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9237",
            "ConditionBrowseLeafName": "Hypothermia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21813",
            "ConditionBrowseLeafName": "Hypoxia-Ischemia, Brain",
            "ConditionBrowseLeafAsFound": "Hypoxia-Ischemia, Brain",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M4356",
            "ConditionBrowseLeafName": "Brain Diseases",
            "ConditionBrowseLeafAsFound": "Encephalopathy",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M14775",
            "ConditionBrowseLeafName": "Signs and Symptoms, Respiratory",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4894",
            "ConditionBrowseLeafName": "Central Nervous System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4962",
            "ConditionBrowseLeafName": "Cerebrovascular Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16552",
            "ConditionBrowseLeafName": "Vascular Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4935",
            "ConditionBrowseLeafName": "Hypoxia, Brain",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          }
        ]
      }
    }
  }
}